{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:09:03Z","timestamp":1778771343180,"version":"3.51.4"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Science and Technology Govt. of India","award":["DST-STI-POLICY FELLOWSHIP (4th Cohort)"],"award-info":[{"award-number":["DST-STI-POLICY FELLOWSHIP (4th Cohort)"]}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>India has a massive burden of rare diseases (RDs), with an estimated 96 million people living with RDs but limited options for treatment. Repurposing drugs used for other common conditions are essential alternative for RDs due to their cost-effectiveness and reduced timeline. India\u2019s patent regime prevents the evergreening of drugs, and a large generic manufacturing industry provides ample opportunity to explore the potential of repurposed drugs for treating RDs, known as repurposed orphan drugs (ROD). However, there is no portal or other source for information on orphan drugs in India. This study assesses the availability of RODs in India through quantitative analysis. In the absence of a separate orphan drug designation in India, we consider USFDA-approved orphan-designated products as the reference. We searched USFDA-approved RODs in recognized sources in India, such as CDSCO, AYUSH gazette, FSSAI, and Indian Pharmacopeia, which provides a list of drugs approved for marketing in India. We classified the drugs into separate groups based on their record from different sources and explored the regulatory implications of the differential representations. We found that almost 76% of the USFDA-approved RODs are listed in one of the Indian regulatory bodies\u2019 records either in the same form (61%) or in a different fixed-dose combination. For 67 drugs no information was found, these drugs have to be imported for use. Only 17 of the 43 RDs mentioned in the National Policy for Rare Diseases, matched the indications listed for approval of one of the 279 RODs identified in the study. This underscores the scarcity of RD treatment and the pressing need for accessibility in India. This information on RODs will help relevant stakeholders to efficiently manage RDs in India. The study also highlights existing gaps in Indian regulatory databases that limits access to accurate information about the availability of drugs.<\/jats:p>","DOI":"10.1371\/journal.pgph.0001498","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T17:25:35Z","timestamp":1695835535000},"page":"e0001498","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of the availability of repurposed orphan drugs in India"],"prefix":"10.1371","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-7793","authenticated-orcid":true,"given":"Khujith","family":"Rajueni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-9702","authenticated-orcid":true,"given":"Mohua","family":"Chakraborty Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"pgph.0001498.ref001","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajmg.a.61124","article-title":"The burden of rare diseases","volume":"179","author":"CR Ferreira","year":"2019","journal-title":"Am J Med Genet A"},{"key":"pgph.0001498.ref002","year":"2021","journal-title":"Ministry of Health and Family Welfare, Government of India. National Policy for Rare Diseases"},{"key":"pgph.0001498.ref003","unstructured":"Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India. Frequently Asked Questions (FAQs) on New Drugs and Clinical Trials. In: CDSCO website [Internet]. New Delhi. 2019 November [cited 2022 Jun 23]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadPublic_NoticesFiles\/faqnd.pdf."},{"key":"pgph.0001498.ref004","author":"Rare disease outlook 2020: Drug development challenges","year":"2020","journal-title":"Pharmaceutical Technology"},{"issue":"4","key":"pgph.0001498.ref005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy.","volume":"24","author":"JJ Darrow","year":"2019","journal-title":"Drug Discov Today"},{"key":"pgph.0001498.ref006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug Repurposing for Rare Diseases.","author":"HI Roessler","year":"2021","journal-title":"Trends Pharmacolo Sci"},{"key":"pgph.0001498.ref007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(19)30006-3","article-title":"Spotlight on rare diseases","volume":"7","author":"T. Lancet Diabetes","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"pgph.0001498.ref008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-019-1224-0","article-title":"The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: An interview-based study.","volume":"14","author":"MC Choudhury","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"pgph.0001498.ref009","volume-title":"Historical Evolution of India\u2019s Patent Regime and Its Impact on Innovation in the Indian Pharmaceutical Industry","author":"U. Racherla","edition":"1"},{"key":"pgph.0001498.ref010","unstructured":"Central Drugs Standard Control Organization. Subsequent New Drugs List, Drugs@CDSCO In: SUGAM Portal [Internet].[cited on 2022 October 2022] Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Drugs\/Subsequent-New-Drugs\/. Also available from: https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs."},{"key":"pgph.0001498.ref011","unstructured":"Department of Science & Technology (DST), Technology Development & Transfer (TDT) Division. Application Format For Rare Diseases. In: DST website [Internet].[cited 2022 Jul 27] Available from: https:\/\/dst.gov.in\/sites\/default\/files\/Application%20Format%20For%20Rare%20Diseases.pdf."},{"issue":"4","key":"pgph.0001498.ref012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/ijp.IJP_646_17","article-title":"Orphan drugs: Indian perspective.","volume":"49","author":"H Kumar","year":"2017","journal-title":"Indian J Pharmacol."},{"key":"pgph.0001498.ref013","article-title":"The availability and affordability of orphan drugs for rare diseases in China.","author":"S Gong","year":"2016","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"pgph.0001498.ref014","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13023-021-02022-w","article-title":"Variables affecting pricing of orphan drugs: the Italian case.","volume":"16","author":"C Jommi","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"pgph.0001498.ref015","unstructured":"US Food & Drug Administration. Orphan Drug Designations and Approvals. [cited 01 October 2021] In: USFDA website [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/."},{"key":"pgph.0001498.ref016","unstructured":"US Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. [cited 17 Nov 2021]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"pgph.0001498.ref017","unstructured":"Directorate General of Health Services Ministry of Health & Family Welfare Government of India. Central Drugs Standard Control Organisation(CDSCO). In: CDSCO [Internet] Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/."},{"key":"pgph.0001498.ref018","unstructured":"Government of India, Ministry of Health. Pharmacopoeia of India: (the Indian Pharmacopoeia). New Delhi, 2018 [cited 2021 December 06]."},{"key":"pgph.0001498.ref019","unstructured":"Food Safety and Standards Authority of India (FSSAI). Guidance Note on Food for Special Medicinal Purpose.[cited 2022 July 06] Available from: https:\/\/fssai.gov.in\/upload\/uploadfiles\/files\/Guidance_Note_FSMP_28_08_2020.pdf."},{"key":"pgph.0001498.ref020","unstructured":"Ministry of Ayush, Government of India, Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH). In: AYUSH website [Internet] Available from: https:\/\/main.ayush.gov.in\/about-the-ministry\/."},{"key":"pgph.0001498.ref021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2393861719883063","article-title":"Globalisation of South Asian Medicines: Knowledge, Power, Structure and Sustainability.","author":"V. Sujatha","year":"2020","journal-title":"Society and Culture in South Asia. Sage Publications"},{"key":"pgph.0001498.ref022","unstructured":"Pharmaffiliates. Sodium Phenylacetate. [cited 27 June 2022] In: Pharmaffiliates commercial webpage [Internet] Available from: https:\/\/www.pharmaffiliates.com\/en\/114-70-5-sodium-phenylacetate-pa2700068.html."},{"key":"pgph.0001498.ref023","author":"Food Safety and Standards Authority of India (FSSAI)","year":"2016","journal-title":"Food Safety And Standards (Health Supplements, Nutraceuticals, Food For Special Dietary Use, Food For Special Medical Purpose, Functional Food And Novel Food) Regulations,"},{"issue":"3","key":"pgph.0001498.ref024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/2229-3485.159935","article-title":"Regulating off-label drug use in India: The arena for concern","volume":"6","author":"S. Oberoi","year":"2015","journal-title":"Perspect Clin Res"},{"key":"pgph.0001498.ref025","unstructured":"GlobalData Healthcare. The potential of drug repurposing in orphan drug development. In: Pharmaceutical Technology Blog [Internet]. [cited 24 June 2022] Available from: https:\/\/www.pharmaceutical-technology.com\/comment\/potential-drug-repurposing-orphan-drug-development\/."},{"issue":"7","key":"pgph.0001498.ref026","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/bcp.13240","article-title":"Affordable orphan drugs: a role for not-for-profit organizations","volume":"83","author":"EH Davies","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pgph.0001498.ref027","first-page":"010402","article-title":"Availability of brands of six essential medicines in 124 pharmacies in Maharashtra","volume":"8","author":"C Millard","year":"2018","journal-title":"J Glob Health. 2018"},{"key":"pgph.0001498.ref028","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine\u2014A life-saving drug for leishmaniasis-is unavailable to people who need it the most","volume":"3","author":"T Sunyoto","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pgph.0001498.ref029","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-019-1093-6","article-title":"The role of patient organizations in the rare disease ecosystem in India: An interview based study.","volume":"14","author":"MC Choudhury","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"pgph.0001498.ref030","unstructured":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare, Government Of India. Policy Guidelines For Approval Of Fixed Dose Combinations (FDCs). [cited 2022 June 25]. Available from: https:\/\/main.mohfw.gov.in\/sites\/default\/files\/6404452866Kokate%20Report.pdf."},{"key":"pgph.0001498.ref031","author":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare, Government Of India","year":"2019","journal-title":"Drugs Controller General of India"},{"key":"pgph.0001498.ref032","author":"FDA Reader","year":"2019","journal-title":"How the FDA Regulates Nutraceuticals"},{"key":"pgph.0001498.ref033","author":"Center for Drug Evaluation and Research, US Food & Drug Administration Botanical","year":"2016","journal-title":"Drug Development Guidance for Industry."},{"issue":"12","key":"pgph.0001498.ref034","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.3390\/ijms21124424","article-title":"Nutraceuticals in Neurological Disorders.","volume":"21","author":"R Makkar","year":"2020","journal-title":"Int J Mol Sci."},{"key":"pgph.0001498.ref035","article-title":"Government to Madras HC: Will form panel of Ayush experts to treat rare disease","author":"TNN","year":"2019","journal-title":"The Times of India Newspaper website"},{"key":"pgph.0001498.ref036","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-16-8822-5_15","article-title":"Traditional, Cultural, and Nutraceutical Aspects of Cannabis in India.","author":"J Govindasamy","year":"2022","journal-title":"Cannabis\/Marijuana for Healthcare. Singapore: Springer Nature"},{"key":"pgph.0001498.ref037","article-title":"Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals.","author":"Office of the Controller General of Patents, Designs and Trademarks","year":"2014"},{"key":"pgph.0001498.ref038","unstructured":"CDSCO, Ministry of Health and Family Welfare, Government of India. Notice: Procedures To Import Small Quantities Of Drugs For Personal Use. [cited 2022 June 25] Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadConsumer\/ProcedureforpermissiontoImportSmallQuantitiesofDrugsForPersonalUse_link.pdf."},{"key":"pgph.0001498.ref039","unstructured":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare, Government Of India. written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with article 46b(2)(b) of directive 2001\/83\/ EC. [cited 2023 July 25]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadInternationalCell\/WC%20-0107%20-Centaur%20(1).pdf."},{"key":"pgph.0001498.ref040","unstructured":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare, Government Of India. written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with article 46b(2)(b) of directive 2001\/83\/ EC. [cited 2023 July 25]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadInternationalCell\/WC%20-0383%20-MSN.pdf."},{"key":"pgph.0001498.ref041","unstructured":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare, Government Of India. written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with article 46b(2)(b) of directive 2001\/83\/EC. [cited 2023 July 25]. Available from: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadInternationalCell\/WC%20-0310%20-Glenmark.pdf."},{"key":"pgph.0001498.ref042","author":"Central Drugs Standard Control Organization, Directorate General Of Health Services, Ministry Of Health & Family Welfare","year":"2001","journal-title":"Government Of India. written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with article 46b(2)(b) of directive"},{"issue":"12","key":"pgph.0001498.ref043","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/d41573-021-00045-3","article-title":"Orphan drug designation and development in Japan: 25 years of experience and assessment.","volume":"20","author":"K Sakushima","year":"2021","journal-title":"Nat Rev. Drug Discov"},{"key":"pgph.0001498.ref044","article-title":"Brazil Approved 21 Orphan Drugs in 2019","author":"Eversana","year":"2020","journal-title":"Eversana Blog"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0001498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T17:26:00Z","timestamp":1695835560000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0001498"}},"subtitle":[],"editor":[{"given":"Habib Hasan","family":"Farooqui","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0001498","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}